<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-046692</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab</dc:title>
<dc:description xml:lang="en">Infliximab, a chimeric monodonal antibody, is a TNF-alfa inhibitor approved for use in refractory rheumatoid arthritis and Crohn's disease. We present the case of a patient affected by severe rheumatoid arthritis who was successfully treated with infliximab. She suffered diverse neurological complications: brachial plexitis, asymptomatic thoracic myelitis with extensive lesions in MRI study, and herpes zoster lumbar plexitis. We review the neurological adverse effects of infliximab (aseptic meningitis, opportunistic germs infections, disseminated herpes zoster) and focus in their potential adverse effect to induce central and peripheral nervous system demyelination</dc:description>
<dc:creator>Arias, M</dc:creator>
<dc:creator>Dapena, D</dc:creator>
<dc:creator>Arias-Rivas, S</dc:creator>
<dc:creator>Mera, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El infliximab es un anticuerpo monoclonal quimérico con acción anti-TNF-alfa que se utiliza eficazmente en el tratamiento de la artritis reumatoide agresiva y de la enfermedad de Crohn fistulosa. Se presenta el caso de una paciente con artritis reumatoide agresiva, tratada satisfactoriamente con infliximab, que sufrió complicaciones neurológicas de diversa índole: plexitis braquial idiopática, mielitis dorsal paucisintomática, aunque con lesiones extensas en la resonancia magnética, y plexitis lumbar por herpes zoster. Se revisan las complicaciones neurológicas del infliximab (meningitis aséptica, infecciones por gérmenes oportunistas, herpes zoster diseminado) y en particular su efecto desencadenante de procesos desmielinizantes, tanto del sistema nervioso central como periférico</dc:description>
<dc:source>Neurologia;20(7): 374-376, sept. 2005. ilus</dc:source>
<dc:identifier>ibc-046692</dc:identifier>
<dc:title xml:lang="es">Plexitis lumbar por herpes zoster, mielitis y plexitis braquial en paciente tratada con infliximab</dc:title>
<dc:subject>^d6721^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2616^s22053</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d2616^s22036</dc:subject>
<dc:subject>^d9379^s22053</dc:subject>
<dc:subject>^d22935</dc:subject>
<dc:subject>^d920^s22020</dc:subject>
<dc:subject>^d9379^s22036</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d32355^s22020</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d32355^s22073</dc:subject>
<dc:subject>^d8335^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>200509</dc:date>
</metadata>
</record>
</ibecs-document>
